|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 18/11 | Panacea Life Sciences Holdings and Benivita Inc. Launch Benivita PLSH | CI |
| 06/24/06 | Panacea Life Sciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Market Cap | 5L 5L 4L 4L 7L 4.95Cr 7L 49.5L 19.43L 2.47Cr 19.49L 19.06L 8.27Cr | P/E 2022 |
-0.11x | P/E 2023 | -0.31x |
|---|---|---|---|---|---|
| Enterprise Value | 2.2Cr 1.92Cr 1.78Cr 1.64Cr 3.09Cr 210.48Cr 3.14Cr 21Cr 8.25Cr 104.78Cr 8.28Cr 8.1Cr 351.36Cr | EV / Sales 2022 |
11.6x | EV / Sales 2023 | 10.1x |
| Free-Float |
-
| Yield 2022 * |
-
| Yield 2023 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -2.44% | -6.49% | +45.62% | +149.31% | 1,02400Cr | ||
| -1.53% | -5.37% | +47.14% | +47.48% | 62TCr | ||
| -2.05% | -4.39% | +24.57% | +64.80% | 44TCr | ||
| +0.24% | -1.69% | +38.82% | +32.61% | 35TCr | ||
| -1.41% | -3.03% | +31.76% | +39.93% | 30TCr | ||
| -8.65% | -10.69% | +3.36% | +5.60% | 26TCr | ||
| -7.65% | -7.72% | -3.74% | -43.86% | 21TCr | ||
| -1.51% | +0.94% | +25.78% | +64.62% | 21TCr | ||
| -0.24% | -0.97% | +12.88% | +71.14% | 16TCr | ||
| Average | -2.17% | -1.35% | +25.13% | +47.96% | 39.71TCr | |
| Weighted average by Cap. | -2.17% | -2.17% | +32.82% | +70.38% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 16.27L 14.14L 13.16L 12.09L 22.82L 16Cr 23.18L 1.55Cr 60.9L 7.73Cr 61.1L 59.76L 26Cr | 23.85L 20.73L 19.3L 17.72L 33.46L 23Cr 33.98L 2.27Cr 89.27L 11Cr 89.57L 87.6L 38Cr |
| Net income | -91.43L -79.48L -73.98L -67.92L -1.28Cr -87Cr -1.3Cr -8.72Cr -3.42Cr -43Cr -3.43Cr -3.36Cr -145.69Cr | -80.15L -69.68L -64.85L -59.54L -1.12Cr -77Cr -1.14Cr -7.64Cr -3Cr -38Cr -3.01Cr -2.94Cr -127.73Cr |
| Net Debt | 1.79Cr 1.55Cr 1.44Cr 1.33Cr 2.5Cr 170.43Cr 2.54Cr 17Cr 6.68Cr 85Cr 6.71Cr 6.56Cr 284.51Cr | 2.15Cr 1.87Cr 1.74Cr 1.6Cr 3.02Cr 205.52Cr 3.07Cr 21Cr 8.06Cr 102.32Cr 8.09Cr 7.91Cr 343.09Cr |
Employees
-
Sector
Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
















